课题基金 / 基金详情

PHASE II PILOT TRIAL OF CONCURRENT BIOCHEMOTHERAPY WITH CISPLATIN, DACARBAZINE

PHASE II PILOT TRIAL OF CONCURRENT BIOCHEMOTHERAPY WITH CISPLATIN, DACARBAZINE
顺铂、达卡巴嗪同步生物化疗的 II 期试点试验
批准号：
6245550
负责人：
Michael Benjamin Atkins
金额：
$2.82万
依托单位：
TUFTS MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-05-01 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6245550
关键词：
cis platinum compound clinical research combination cancer therapy combination chemotherapy dacarbazine human subject human therapy evaluation interferon alpha interleukin 2 intravenous administration neoplasm /cancer neoplasm /cancer chemotherapy vinblastine

项目摘要

项目成果

Michael Benjamin Atkins的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This study will involve the intravenous administration of DTIC, CDDP, and Vinblastine concurrent with subcutaneous administration of alpha- interferon (Intron A) and a four-day continous infusion of IL-2. The purpose of this study is to determine whether the administration of DTIC and CDDP and Vinblastine in combination with a continuous infusion of IL-2 and subcutaneous injections of interferon is capable of having an effect on the growth of tumors. We also hope to determine the side effects of this regimen and the potential feasibility of carrying out this treatment in community hospital settings.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors
  • 批准号：
    10462570
  • 项目类别：
  • 资助金额：
    $52.27万
  • 财政年份：
    2018
  • 负责人：
    Michael Benjamin Atkins
  • 依托单位：
    GEORGETOWN UNIVERSITY
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors
  • 批准号：
    10001451
  • 项目类别：
  • 资助金额：
    $53.33万
  • 财政年份：
    2018
  • 负责人：
    Michael Benjamin Atkins
  • 依托单位：
    GEORGETOWN UNIVERSITY
Career Development Program
Developmental Research Program
海外基金